COLLEGEVILLE, Penn--A patient with advanced non-small-cell lung
cancer has become the first to receive an injection of a p53/retrovirus
gene therapy into existing tumor cells, Introgen Therapeutics,
Inc. and RPR Gencell, a division of Rhône-Poulenc Rorer,
The phase I study is being conducted by Jack A. Roth, MD, at The
University of Texas M.D. Anderson Cancer Center, where he is chairman
of the Department of Thoracic and Cardiovascular Surgery.
The retrovirus vector delivers normal p53 genes into cancer cells
in an attempt to restore normal cellular control. The patient
received the dose into the tumor bed after surgical excision and
will be given four more doses.